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Objective: Despite the intense debate concerning the prognostic 
impact of fissure involvement (FI) in patients with non–small-cell 
lung cancer, no specific surgical strategies have been yet recom-
mended when this condition occurs. In this setting, we report our 
monocentric 10-years experience to investigate this issue.
Methods: From January 2000 to January 2010, the clinical data of 
40 non–small-cell lung cancer patients with FI undergoing curative 
resection were retrospectively reviewed. The sample was stratified 
according to the type of resection: group A (28 patients): anatomical 
resection (bilobectomy [21 patients], pneumonectomy [7 patients]); 
group B (12 patients): nonanatomical resection (lobectomy plus 
wedge resection [LWR]). The end-points were (1) impact of different 
surgical approach on the pulmonary function (measured before sur-
gery and 1 month after discharge); (2) disease-specific survival; and 
(3) tumor recurrence.The t test, χ2, and log-rank tests, Kaplan–Meier 
method, and Cox and logistic regression analyses were used for the 
statistical analysis.
Results: No differences between the two groups were found when 
comparing the clinical characteristics, histology, pN or pT sta-
tus, p-stage, residual (R1) disease, tumor grading, or tumor size. 
Similarly, the baseline preoperative function (tested as forced expi-
ratory volume in 1 second-%-predicted, FEV1%) was likewise 
comparable (92.5% ± 21.0% in group A versus 85.2% ± 20.0% in 
group B; p = not significant). The decline of FEV1% after surgery 
was slightly higher in group A (−24.9% ± 13.5%) when compared 
with that in group B (−19.5% ± 13.3%), but this difference was not 
statistically significant (p = ns). Nevertheless, the 5-year disease-
specific survival was 56% for group A and 47% for group B (p = ns). 
The recurrence rate did not differ between the patients undergoing a 
LWR (3 of 12 patients) and those undergoing a bilobectomy or pneu-
monectomy (9 of 28 patients) (p = ns). The presence of FI extended 
for more than 3 cm was found to be the most significant prognos-
tic factor when analyzing survival (p = 0.002) and recurrence rate 
(p < 0.001).
Conclusions: Our results suggest that nonanatomical resection 
(LWR) could be considered as a feasible surgical option (especially 
in “frail” patients with an extent of FI less than 3 cm) in the light of 
the similar oncological and functional outcome compared with ana-
tomical resection. Further studies based on larger series are needed 
to confirm these preliminary data and also to investigate the impact 
on the postoperative quality of life.
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(J Thorac Oncol. 2014;9: 97–108)
Although visceral pleural invasion (VPI) is accepted as one of the most important prognostic factors in non–small-cell 
lung cancer (NSCLC) surgical series,1,2 the prognostic impact 
of fissure involvement (FI) alone was only rarely analyzed 
and reported in the English literature.3,4 The 6th tumor, node, 
metastasis (TNM) classification of the Union for International 
Cancer Control, as well, has not clearly defined the criteria to 
assign a specific T factor to a tumor that invades through the 
interlobar pleura into one of the adjacent lobes.5 In the 7th 
TNM classification,6 NSCLCs with FI are classified as T2a, 
unless other T factors induce a higher category, regardless of 
the type of FI (interlobar pleura only or transfissural into the 
parenchyma of the adjacent lobe). As the new TNM staging 
system does not consider the FI status, no specific surgical 
strategies have been yet recommended when this condition 
occurs. Moreover, available data refer mainly to survival and 
recurrence rates whereas reports focusing on the quality of life 
and postoperative pulmonary function are absent.
In this monocentric study, we have analyzed the long-
term (5 year) survival outcomes and recurrence rates of 
NSCLCs that extend across the fissure into the adjacent lobe 
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and that required either an anatomical (bilobectomy or pneu-
monectomy) or a nonanatomical resection (lobectomy plus 
wedge resection [LWR]). Moreover, this study analyzes and 
reports about the impact of the type of resection on the early-
term outcome in terms of pulmonary function.
PATIENTS AND METHODS
Patients Selection
After obtaining approval of this study by our Institutional 
Review Board, the clinical records of all patients (1080 cases) 
who underwent surgery for NSCLC in the Department of 
Thoracic Surgery at “Agostino Gemelli” General Hospital in the 
period between January 2000 and January 2010 were retrospec-
tively reviewed. Patients with small-cell carcinoma, neoadju-
vant treatment, macroscopic positive surgical margin, superior 
sulcus tumor, pathological N3 disease, or distant metastasis 
were excluded. Patients with pathological stages T2, T3 (tumor 
size higher than 7 cm or chest wall invasion), or T4 (satellite 
lesions in a separate lobe) were included in the study. We have 
identified 40 patients with direct adjacent lobe invasion, defined 
as contiguous extension of the primary tumor across the fissure 
into another lobe as confirmed by histopathologic examina-
tion. Lesions showing invasion as limited only into the visceral 
pleura of the adjacent lobe were also included. The preoperative 
workup included routine biochemical tests, electrocardiograph, 
chest radiograph, fiber-optic bronchoscopy, computed tomog-
raphy scan, positron emission tomography scan (as of January 
2005), and perfusion lung scan. Mediastinoscopy, endoscopic 
ultrasound–fine-needle aspiration, and endobronchial ultra-
sound-guided transbronchial needle aspiration were performed 
for diagnosing N2, N3, or M1 disease. The pulmonary func-
tion was measured using a volume-displacement body plethys-
mograph (Platinum Elite; Medical Graphics Corporation, St. 
Paul, MN). Lung volumes and single-breath diffusion capac-
ity for carbon monoxide (DLCO) were measured according to 
the recent American Thoracic Society/European Respiratory 
Society guidelines. Functional tests were expressed as absolute 
values and as percent of the predicted; these were performed 
before surgery and 1 month after discharge. Pulmonary function 
tests were available for the half of the total sample. Resection 
types were stratified in two groups: bilobectomy or pneumonec-
tomy (anatomical resection, group A) and LWR (nonanatomical 
resection, group B). Decision regarding the type of resection 
was based, in each patient, on the surgeon’s preference accord-
ing to the pulmonary reserve of the patient and the localization 
of the tumor if eligible for partial resection. Systematic medi-
astinal lymph node dissection was routinely performed in all 
patients. Pathological staging was carried out according to the 
7th TNM classification.6 Follow-up data regarding the clinical 
outcome were collected from the patients’ charts and direct 
interviews of the patients, their next of kin, and their general 
practitioners. Oncological follow-up data were available for 
90% of sample (36 patients).
Statistical Analysis
The sample characteristics were summarized by abso-
lute and relative frequencies for categorical variables and 
by means ± SDs for continuous variables. Univariate analy-
sis was performed to verify the comparability of group A 
and group B on major demographic, clinical, surgical, and 
oncological factors. The Student’s t test was applied to 
continuous variable, with correction for unequal variances 
when required, and the Pearson’s χ2 test (or the Fisher’s 
exact test for expected cell frequencies less than 5) for cat-
egorical variables. The groups of subjects who underwent 
one of the two different surgical procedures were compared 
with regard to all spirometric and blood gas parameters on 
the percentage change from baseline, this being calculated 
as Δ = [(postoperative − baseline/baseline) × 100] with a 
Student’s t test.
The occurrence of postoperative complications and 
the need for hospital stay longer than 6 days were investi-
gated by means of a logistic regression analysis. Potentially 
associated factors considered for these analyses were 
type of surgery, forced vital capacity (FVC) 85% or less, 
forced expiratory volume in 1 second (FEV1) 85% or less, 
DLCO 15 or less, pO
2
 80 mmHg or less, comorbidities, and 
complications.
Mortality and recurrence were investigated with a sur-
vival analysis. Overall survival (OS) and disease-specific 
survival (DSS) were defined as the time from date of surgery 
until the event of interest (death from any cause [for OS] 
or disease-specific death [for DSS]) or alive at last follow-
up (censored). Disease-free survival (DFS) was defined 
as the time from date of surgery until evidence of tumor 
recurrence (event) or no evidence of tumor recurrence at 
last follow-up (censored). Sociodemographic and clinically 
meaningful factors, potentially associated to these two out-
comes, were age, sex, smoking habits, type of surgery, pR1 
resection, extent of FI higher than 3 cm, pathological T and 
N status, tumor size, and histology. Kaplan–Meier analysis 
was performed and survival curves were compared with 
the log-rank test. Cox regression analysis was also imple-
mented to explore the prognostic role of several variables 
on patients’ DSS and DFS. Multivariable Cox proportional 
hazards regression models for DSS and DFS were selected 
in a forward-stepwise manner (forward selection): all fac-
tors listed above were fitted one at a time and the factor 
predictive of the highest statistically significant hazards of 
mortality was selected; subsequently, in a forward-stepwise 
manner, all remaining factors were fitted, one at a time, to the 
selected model and the new models evaluated for their sta-
tistical significance and reliability (acceptable hazard ratio 
[HR] estimates and 95% confidence intervals) in predicting 
mortality or recurrence hazards. The procedure continued, in 
loop, until no other factor could be entered with reliability 
and statistical significance into the models. Proportionality 
of hazards was tested for all factors with the Grambsch and 
Therneau’s test.
A similar forward-stepwise procedure was applied to 
the logistic regression analysis. The limit for statistical sig-
nificance was set at p value less than 0.05. All tests were two-
sided. Given the small sample size, all analyses were intended 
as explorative. STATA/SE V12.0 software package was used 
for all statistical analyses.
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RESULTS
Clinical and Surgical Data
According to the histopathologic examination, we have 
identified 40 NSCLC patients with direct adjacent lobe inva-
sion by the primary tumor. The demographic and clinicopatho-
logical characteristics of the total sample are summarized in 
Table 1. The primary tumor was in the right lung in 29 patients 
and in the left lung in 11 patients. The lesions were localized 
in the upper lobe in 21 cases, in the lower in 12 patients, and 
in the middle lobe in five patients; two patients had a cancer 
located centrally (hylum). Regarding the T factor, 28 lesions 
(70%) were pathologically classified as T2 (T2a in 22 cases 
and T2b in 6 cases), whereas T3 tumor was found in 11 patients 
(27.5%) (for tumor size higher than 7 cm and for chest wall 
invasion, respectively, in 10 and 1 case); only one patient was 
staged as T4 for the presence of a satellite lesion in a separate 
lobe. Among T2a lesions, a pure interlobar visceral pleura inva-
sion was carried out in six patients only. Twenty-three patients 
(58%) had no nodal metastases (N0 disease), 11 (27%) had a 
N1 disease, and six (15%) had mediastinal nodal metastases 
(N2 disease). The histopathologic staging of the total sample 
was as follows: IB 32%, IIA 25%, IIB 15%, and IIIA 28%. 
Pathological examination identified squamous cell carcinoma 
in 13 patients (32%), adenocarcinoma (AC) in 15 (38%), and 
other histologies in 12 cases (30%). The average pathological 
tumor size was 4.69 ± 2.21 cm (range, 1.0–9.0 cm); the extent 
of FI higher than 3 cm was confirmed in 10 patients. A micro-
scopic residual disease (R1) was detected in six patients (15%).
According to the extent of the pulmonary resection, we 
have stratified the sample in two groups: 28 patients with ana-
tomical resection (group A) and 12 patients with nonanatomi-
cal resection (group B). Among those patients in the group A, 
we have performed 21 bilobectomies (75%) and seven pneu-
monectomies (25%). In all the patients of the group B, we 
have performed a LWR. No differences between the two 
groups were found when comparing the clinical characteris-
tics, histology, pN or pT status, p-stage, residual (R1) disease, 
tumor grading, tumor size (Table 1). The presence of an FI 
higher than 3 cm was proven in 10 patients of the group A only 
(p = 0.017).
Pulmonary Function Data
Functional test values were performed before sur-
gery (baseline) and 1 month after discharge (postoperative). 
Baseline lung volumes, DLCO, and blood gas analyses are 
summarized in Table 2. The baseline preoperative tests were 
likewise comparable between both groups: in particular, pre-
operative FEV1%-predicted of group A and group B were, 
respectively, 92.5% ± 21.0% and 85.2% ± 20.0% (p = ns).
To evaluate the impact of the two different surgical 
approaches on the early-term functional outcome, we have 
analyzed the decline of FEV1 % (ΔFEV1%) after surgery, 
measured before surgery and 1 month after discharge. The 
ΔFEV1% was slightly higher in patients undergoing bilobec-
tomy or pneumonectomy (−24.9% ± 13.5%) if compared with 
those undergoing LWR (−19.5% ± 13.3%), but this difference 
was not statistically significant (p = ns). We reported similar 
results when comparing the decline of FVC %, DLCO, and 
pO
2
 as well (Table 3).
Postoperative Data
Fifteen patients were admitted in the intensive care 
unit (ICU) with an average stay of 0.47 ± 0.68 days (range, 
0–3 days). The mean hospital stay of the total sample was 
11.72 ± 7.32 days (range, 5–33 days). Ten patients (25%) expe-
rienced a postoperative complication. Postoperative major and 
minor complications occurred, respectively, in six (15%) and 
in seven (17%) cases: in particular we evidenced pneumo-
nia in one case, bleeding (not requiring reoperation) in four 
patients, respiratory failure (not requiring reintubation) in one 
case, atelectasis in one case, air leak in four patients, and atrial 
fibrillation in two cases. There was no 30-day postoperative 
mortality. After surgery, 22 patients (55%) received adjuvant 
therapy (chemotherapy in 18 and radiotherapy in 12 cases, 8 
of which received both therapies).
No differences between group A and group B were 
found when comparing adjuvant treatment, postoperative 
complications, admission and length of stay in the ICU, and 
hospital stay (Table 1).
The type of resection, comorbidities, FVC% less than 
85%, FEV1% less than 85%, DLCO less than 15, and pO
2
 less 
than 80 mmHg were evaluated as potential predictors of post-
operative complications; however, logistic regression analysis 
found no statistically significant association with these factors 
(Table 4). Moreover, we did not find any correlation between 
hospital stay longer than 6 days and extent of surgery, postop-
erative complications, FVC% less than 85%, FEV1% less than 
85%, DLCO less than 15, and pO
2
 less than 80 mmHg (Table 4).
Survival
The mean follow-up time was 41.64 ± 34.07 months 
(range, 6–154 months). The median OS time of the total sam-
ple (n = 36) was 49 months: in particular the median DSS time 
for group A and group B (n = 30) was, respectively, 64 and 60 
months (p = ns). The 5-year OS rate was 42%. The 5-year OS 
based on resection type was 48% in group A and 33% in group 
B (p = ns; Fig. 1). In particular, the 5-year DSS was 56% for 
group A and 47% for group B (p = ns; Fig. 1): we have evi-
denced disease-specific deaths in group A and B, respectively, 
in eight and four patients.
The evaluated prognostic factors in statistical analyses 
were age, sex, smoking history, type of surgery, postoperative 
complications, histology, pT status, pN status, p-stage, tumor 
size, extent of FI, and pR1 resection. From the simple Cox 
regression analysis, it emerged that the hazards of mortality 
for extent of FI (FI >3 cm versus ≤3 cm: HR = 6.95 [2.02; 
23.96]; p = 0.002) and pN (pN1 versus pN0: HR = 1.31 [0.33; 
5.26]; p = 0.70; pN2 versus pN0: HR = 6.22 [1.27; 30.41]; 
p = 0.024) were statistically significant. In particular, the 
extent of FI was the strongest predictive factor (Fig. 1). When 
fitting this factor and, one at a time, all remaining variables 
into a multivariable Cox regression model, no other factor was 
found to be predictive of mortality hazards to a statistically 
significant level. Table 5 shows results for simple and multi-
variable Cox regression models.
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TABLE 1.  Characteristics of the Total Sample and Comparison between Group A and Group B





Lobectomy Plus Wedge 
Resection (n = 12) pa
Age (yr) 66.32 ± 9.80 66.61 ± 10.42 65.67 ± 8.56 0.785
Age
  ≤65 yr 13 (32%) 9 (32%) 4 (33%) 0.941
  >65 yr 27 (68%) 19 (68%) 8 (67%)
Sex
  Female 9 (22%) 6 (21%) 3 (25%) 0.804
  Male 31 (78%) 22 (79%) 9 (75%)
Smoker
  No 22 (69%) 16 (67%) 6 (75%) 0.660
  Yes 10 (31%) 8 (33%) 2 (25%)
Pack-years 39.16 ± 34.91 44.91 ± 34.99 24.79 ± 33.13 0.242
Pulmonary comorbidities
  No 13 (33%) 9 (33%) 4 (33%) 1.000
  Yes 26 (67%) 18 (67%) 8 (67%)
Cardiovascular comorbidities
  No 17 (44%) 11 (41%) 6 (50%) 0.590
  Yes 22 (56%) 16 (59%) 6 (50%)
Diabetes
  No 33 (85%) 22 (81%) 11 (92%) 0.416
  Yes 6 (15%) 5 (19%) 1 (8%)
Other comorbidities
  No 18 (46%) 12 (44%) 6 (50%) 0.748
  Yes 21 (54%) 15 (56%) 6 (50%)
Side
  Right 29 (72%) 21 (75%) 8 (67%) 0.589
  Left 11 (28%) 7 (25%) 4 (33%)
Localization
  Hilar 2 (5%) 2 (7%) 0 (0%) 0.205
  Upper lobe 21 (52%) 17 (61%) 4 (33%)
  Middle lobe 5 (13%) 3 (11%) 2 (17%)
  Lower lobe 12 (30%) 6 (21%) 6 (50%)
cT
  T1 8 (22%) 3 (12%) 5 (45%) 0.117
  T2 20 (54%) 15 (58%) 5 (45%)
  T3 8 (22%) 7 (27%) 1 (9%)
  T4 1 (3%) 1 (4%) 0 (0%)
cN
  N0 26 (68%) 19 (73%) 7 (58%) 0.609
  N1 6 (16%) 3 (12%) 3 (25%)
  N2 5 (13%) 3 (12%) 2 (17%)
  N3 1 (3%) 1 (4%) 0 (0%)
cStage
  IA 5 (14%) 2 (8%) 3 (27%) 0.581
  IB 11 (30%) 9 (35%) 2 (18%)
  IIA 5 (14%) 4 (15%) 1 (9%)
  IIB 8 (22%) 5 (19%) 3 (27%)
  IIIA 7 (19%) 5 (19%) 2 (18%)
  IIIB 1 (3%) 1 (4%) 0 (0%)
cTumor size (cm) 4.50 ± 2.19 4.80 ± 2.12 3.8 ± 2.28 0.206
PET
  No 27 (71%) 17 (65%) 10 (83%) 0.257
  Yes 11 (29%) 9 (35%) 2 (17%)
(Continued)
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Residual disease
  R0 34 (85%) 25 (89%) 9 (75%) 0.246
  R1 6 (15%) 3 (11%) 3 (25%)
Histology
  SCC 13 (32%) 9 (32%) 4 (33%) 0.420
  AC 15 (38%) 9 (32%) 6 (50%)
  Other 12 (30%) 10 (36%) 2 (17%)
pT
  T2 28 (70%) 18 (64%) 10 (83%) 0.450
  T3 11 (27%) 9 (32%) 2 (17%)
  T4 1 (3%) 1 (4%) 0 (0%)
pN
  N0 23 (58%) 15 (54%) 8 (67%)
  N1 11 (27%) 9 (32%) 2 (17%) 0.602
  N2 6 (15%) 4 (14%) 2 (17%)
p-Stage
  IB 13 (32%) 8 (29%) 5 (42%)
  IIA 10 (25%) 6 (21%) 4 (33%)
  IIB 6 (15%) 5 (18%) 1 (8%) 0.540
  IIIA 11 (28%) 9 (32%) 2 (17%)
pTumor size (cm) 4.69 ± 2.21 4.94 ± 2.12 4.12 ± 2.41 0.289
Tumor size
  ≤4 cm 19 (49%) 12 (44%) 7 (58%) 0.423
  >4 cm 20 (51%) 15 (56%) 5 (42%)
Fissure invasion
  ≤3 cm 30 (75%) 18 (64%) 12 (100%) 0.017
  >3 cm 10 (25%) 10 (36%) 0 (0%)
Tumor grading
  G1 3 (8%) 2 (8%) 1 (10%) 0.973
  G2 18 (50%) 13 (50%) 5 (50%)
  G3 15 (42%) 11 (42%) 4 (40%)
ICU admission
  No 25 (62%) 17 (61%) 8 (67%) 0.722
  Yes 15 (38%) 11 (39%) 4 (33%)
ICU stay (days) 0.47 ± 0.68 0.46 ± 0.58 0.5 ± 0.90 0.881
Hospital stay (days) 11.72 ± 7.32 12.30 ± 7.83 10.42 ± 6.14 0.467
Major postoperative complications
  No 34 (85%) 24 (86%) 10 (83%) 0.847
  Yes 6 (15%) 4 (14%) 2 (17%)
Minor postoperative complications
  No 33 (83%) 22 (79%) 11 (92%) 0.318
  Yes 7 (17%) 6 (21%) 1 (8%)
Adjuvant therapy
  No 18 (45%) 14 (50%) 4 (33%) 0.332
  Yes 22 (55%) 14 (50%) 8 (67%)
Adjuvant chemotherapy
  No 22 (55%) 15 (54%) 7 (58%) 0.781
  Yes 18 (45%) 13 (46%) 5 (42%)
Adjuvant radiotherapy
  No 28 (70%) 22 (79%) 6 (50%) 0.071
  Yes 12 (30%) 6 (21%) 6 (50%)
aStatistical tests: Pearson’s χ2 test for categorical variables and Student’s t test for continuous variables; statistical significance: p < 0.05.
PET, positron emission tomography; SCC, squamous cell carcinoma; AC, adenocarcinoma; ICU, intensive care unit.
TABLE 1. (Continued)
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DFS Analysis
The overall DFS was 62 months (n = 34). Postoperative 
recurrence of total sample was observed in 12 patients: in par-
ticular the local recurrence and distant metastasis were found, 
respectively, in seven and six cases. The recurrence rate did 
not differ between the patients undergoing a LWR (3 of 12 
patients) and those undergoing a bilobectomy or pneumonec-
tomy (9 of 28 patients) (p = ns). The 5-year DFS was 56% for 
both groups (p = ns; Fig. 2).
The recurrence rate was compared according to age, 
sex, smoking history, type of surgery, histology, pT status, pN 
status, p-stage, tumor size, extent of FI, and pR1 resection. 
Similar to DSS, the simple Cox regression analysis evidenced 
that the hazards of recurrence for extent of FI (FI >3 cm ver-
sus ≤3 cm: HR = 12.42 [3.56; 43.24]; p < 0.001) and pR1 
(pR1 versus pR0: HR = 4.70 [1.11; 19.89], p = 0.035) were 
statistically significant. The extent of FI was the strongest 
predictive factor for recurrence also (Fig. 2). When fitting 
the extent of FI and, one at a time, all remaining variables 
into a multivariable Cox regression model, no other factor 
was found to be predictive of recurrence hazards to a statis-
tically significant level, with the exception of AC histology 
TABLE 2.  Baseline Spirometric and Blood Gas Parameters of the Total Sample and Comparison between Group A and Group B
Total (n = 40) Group A (n = 28) Group B (n = 12) pa
pH 7.42 ± 0.02 7.42 ± 0.02 7.43 ± 0.02 0.285
pCO
2
 (mmHg) 38.93 ± 4.35 38.82 ± 4.52 39.42 ± 4.10 0.809
pO
2
 (mmHg) 80.85 ± 8.85 81.21 ± 8.92 79.42 ± 9.74 0.729
FVC (liter) 3.08 ± 0.95 3.13 ± 1.04 2.89 ± 0.51 0.667
FVC (%) 100.19 ± 17.76 100.12 ± 19.07 100.5 ± 12.71 0.970
FEV1 (liter) 2.22 ± 0.68 2.27 ± 0.71 1.995 ± 0.57 0.480
FEV1 (%) 91.15 ± 20.52 92.53 ± 20.99 85.25 ± 19.99 0.537
TLC (liter) 5.20 ± 1.31 5.22 ± 1.36 5.14 ± 1.27 0.919
TLC (%) 92.74 ± 15.73 91.56 ± 14.61 97.75 ± 21.70 0.493
RV (liter) 1.97 ± 0.74 1.92 ± 0.63 2.21 ± 1.20 0.485
RV (%) 93.20 ± 28.65 91.07 ± 22.09 102.25 ± 52.29 0.701
DLCO 15.88 ± 5.75 14.84 ± 5.90 19.28 ± 4.11 0.185
aStatistical tests: Pearson’s χ2 test for categorical variables and Student’s t test for continuous variables; statistical significance: p < 0.05.
FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; DLCO, diffusion capacity for carbon monoxide; TLC, total lung capacity; RV, residual volume.
TABLE 3.  Spirometric and Blood Gas Analyses before Surgery (Baseline) and 1-Month after Discharge (Postoperative)
Group A Group B
Comparison 
between Type of 
Surgery on Δa
Baseline Postoperative Δa Baseline Postoperative Δa p
FVC (%) 15 13 13 4 4 4 0.306
99.60 ± 20.20 77.54 ± 16.59 −24.02 ± 14.31 100.50 ± 12.71 84.25 ± 12.37 −14.88 ± 17.89
FEV1 (%) 15 13 13 4 4 4 0.494
92.41 ± 22.43 70.92 ± 18.59 −24.9 ± 13.541 85.25 ± 19.99 66.75 ± 6.80 −19.49 ± 13.37
TLC (%) 15 12 12 4 4 4 0.584
92.03 ± 15.51 68.75 ± 10.65 −23.72 ± 10.16 97.75 ± 21.70 77.25 ± 17.00 −20.31 ± 11.71
RV (%) 15 12 12 4 4 4 0.827
93.21 ± 22.69 71.00 ± 22.71 −18.31 ± 27.18 102.25 ± 52.29 76.25 ± 31.36 −21.56 ± 16.91
DLCO 12 9 8 4 3 3 0.386
14.99 ± 6.14 10.64 ± 3.53 0.30 ± 55.12 19.28 ± 4.11 14.40 ± 2.00 −17.75 ± 3.01
pH 15 11 11 4 4 4 0.569
7.42 ± 0.03 7.41 ± 0.02 −0.02 ± 0.40 7.43 ± 0.02 7.42 ± 0.03 −0.16 ± 0.33
pCO
2
 (mmHg) 15 11 11 4 4 4 0.446
38.93 ± 4.82 38.11 ± 2.76 2.68 ± 10.37 39.42 ± 4.10 38.60 ± 2.95 −1.73 ± 6.47
pO
2
 (mmHg) 14 11 11 4 4 4 0.508
81.39 ± 9.44 90.29 ± 10.57 8.98 ± 17.46 79.42 ± 9.74 81.35 ± 10.68 2.64 ± 9.20
Statistical tests: Student’s t test for continuous variables; statistical significance: p < 0.05.
aΔ = (postoperative − baseline/baseline) × 100.
FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; DLCO, diffusion capacity for carbon monoxide; TLC, total lung capacity; RV, residual volume.
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(p = 0.034). Table 6 shows results for simple and multivari-
able Cox regression models.
DISCUSSION
In the English literature, the frequency of NCSLC with 
FI is lower than that of tumors with VPI and ranges from 
2.1% to 17.6%7–12 of operated patients (3.7% in or series). The 
opportunity for a NSCLC to invade the fissure depends on its 
location and the specific lung anatomy: thus, there is more 
chance to observe a FI on the right (as in our series) than on 
the left. Moreover, in each patient the interlobar fissures vary 
in terms of completeness and the FI may be misinterpreted, 
in case of partially or totally incomplete fissure. On the con-
trary, although an interlobar FI was suspicious at the moment 
of operation when the operative field was explored, in most 
of the cases this was pathologically confirmed to be a simple 
interlobar fissure adhesion only.
The 6th TNM classification of the Union for International 
Cancer Control5 has not clearly defined the prognostic impact 
of NSCLC with interlobar extension. On the basis of the 
TABLE 4.  Analysis on the Occurrence of Complications and on Hospital Stay
Complications  
(n = 10 [25%])
No Complications  




  Group A 7 (70%) 21 (70%) 1.00
  Group B 3 (30%) 9 (30%) 1.00 0.21–4.77 1.000
Comorbidity
  No 1 (10%) 3 (10%) 1.00
  Yes 9 (90%) 26 (90%) 1.04 0.10–11.30 0.975
FVC (%)
  >85% 2 (50%) 13 (76%) 1.00
  ≤85% 2 (50%) 4 (24%) 3.25 0.34–31.07 0.306
FEV1 (%)
  >85% 2 (50%) 10 (59%) 1.00
  ≤85% 2 (50%) 7 (41%) 1.43 0.16–12.70 0.749
DLCO
  >15 2 (67%) 8 (57%) 1.00




  ≥80 2 (50%) 8 (47%) 1.00
  <80 2 (50%) 9 (53%) 0.89 0.10–7.86 0.916
Hospital Stay ≤6 days 
(n = 7 [18%])
Hospital Stay >6 days 
(n = 32 [82%])
Unadjusted Odds Ratio 95% Confidence Interval pa
Surgery
  Group A 23 (72%) 4 (57%) 1.00
  Group B 9 (28%) 3 (43%) 0.52 0.10–2.81 0.449
Complications
  No 22 (69%) 7 (100%) 1.00
  Yes 10 (31%) 0 (0%) Not computable
FVC (%)
  >85% 11 (69%) 4 (80%) 1.00
  ≤85% 5 (31%) 1 (20%) 1.82 0.16–20.71 0.630
FEV1 (%)
  >85% 8 (50%) 4 (80%) 1.00
  ≤85% 8 (50%) 1 (20%) 4.00 0.36–44.11 0.258
DLCO
  >15% 8 (62%) 2 (50%) 1.00




  ≥80% 8 (50%) 2 (40%) 1.00
  <80% 8 (50%) 3 (60%) 0.67 0.09–5.13 0.697
aStatistical tests: logistic regression analysis; statistical significance: p < 0.05.
FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; DLCO, diffusion capacity for carbon monoxide; TLC, total lung capacity; RV, residual volume.
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limited data available, the 7th TNM classification6 recom-
mended that tumors with direct invasion of an adjacent lobe 
across the fissure or by direct extension into a fissureless lung 
be categorized as T2a, unless other T factors result in a higher 
T category. Previous works on interlobar spread of NSCLC 
have resulted in highly variable conclusions. Miura et al.3 con-
cluded that interlobar pleural extension makes no difference 
to survival and should be classified as T2. On the contrary, 
Okada et al.4 and Demir et al.7 suggested that NCSLC with 
FI had similar survival to that of T3 tumors. According to the 
pathological stage, Joshi et al.8 reported that the 5-year OS for 
tumors extending across the fissure is placed between those of 
stage I and stage II.
As well, previous data on survival rates are discordant. 
In a series of 50 patients, Nonaka et al.9 reported a 5-year OS 
of 63%. Similar results were described by Haam et al.10 (53%) 
and Joshi et al.8 (50%). On the contrary, a lower survival was 
advocated by Okada et al.,4 Demir et al.,7 and Riquet et al.11 
which showed a similar 5-year OS (respectively 37%, 36%, 
and 38.9%).
The poor survival of patients with NSCLC with FI 
might be explained by the interrelationship between the inter-
lobar visceral pleura and the invading tumor. Normally, VPI 
indicates biological tumor invasiveness and is associated with 
a poor outcome.13 Moreover, lymphatic ducts and blood ves-
sels are abundant in the subpleural space. By penetrating two 
different layers of the visceral pleura, tumors invading the fis-
sure have a high probability to invade small lymphatic ducts 
and blood vessels. In fact, Ohtaki et al.13 reported a statisti-
cally significant association between tumors with FI and vas-
cular/lymphatic invasion, compared with NSCLCs invading 
an incomplete fissure. As reported in literature, this lymphatic 
invasion results in a high rate of lymph node involvement as 
well.3,4,7,9 Although we evidenced a pN0 rate of 58%, other 
authors reported that pN0 is generally inferior to 50% of 
cases, whereas nodal involvement is present in more than two-
third of patients as a result of drainage of invading tumor into 
the adjacent lobe lymphatic system. Even if not confirmed by 
multivariate analysis, our study reported that pN2 was associ-
ated to worse survival as well.
In our series, we reported a 5-year OS of 42%, in line 
with that reported by others.4,7,11 Unlike analyzed in previous 
studies, we estimated the DSS oncologically more accurate 
than OS. In particular, the 5-year DSS was 52% for the total 
sample. According to DSS, the presence of FI higher than 
3 cm (pathologically confirmed in 10 patients) was found to 
be an independent prognostic indicator. The worse survival 
associated with this pattern of invasiveness could be explained 
by two reasons:
1.  In our series, these patients were associated with a 
greater pathological tumor size. The large size of 
NSCLC per se is a well-known factor of poorer prog-
nosis: in fact, the 7th TNM classification reported that 
T3 tumors larger than 7 cm in their major axis have a 
significantly poorer prognosis than other categories of 
T3 (35% versus 41%).14
2.  Seventy percent of patients with FI extended for more 
than 3 cm has a nodal involvement. This supports the 
above-mentioned theory of Ohtaki et al.,13 confirming 
the significant association between tumors with FI and 
lymphatic invasion. However, further studies with larger 
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In the literature, controversies exist on the treatment 
of tumors with FI. Because radical resection of tumors with 
their lymphatic drainage is the accepted oncological proce-
dure, curative resection can only be anticipated in lesions tra-
versing the fissure if all of the involved tissue is anatomically 
removed (by at least bilobectomy or pneumonectomy). Yang 
et al.15 reported that the patients who underwent pneumonec-
tomy or bilobectomy had better survival than patients under-
going LWR. Okada et al.,4 Nonaka et al.,9 and Haam et al.10 
have reported that survival did not differ between the patients 
receiving a lobectomy with the partial resection and those 
receiving an anatomical resection. Furthermore, Demir et al.7 
suggested that LWR or bilobectomy on the right lung may be 
preferable over pneumonectomy in the case of adjacent lobe 
invasion, considering the high mortality and morbidity rate of 
the pneumonectomy. According to DSS, in our series we have 
evidenced a not statistically significant difference between 
patients undergoing anatomical resection (pneumonectomy or 
bilobectomy) and LWR (group A 56% versus group B 47%; 




(n = 12 [40%])
Alive  















  ≤65 6 (50%) 5 (28%) 1.63 0.52–5.13 0.403 0.88 0.25–3.08 0.839 103
  >65 6 (50%) 13 (72%) 1 1 154
Sex
  Female 1 (8%) 6 (33%) 1 1 45
  Male 11 (92%) 12 (67%) 1.86 0.23–15.29 0.564 1.24 0.14–10.64 0.846 154
Smoker
  No 6 (67%) 11 (73%) 1 1 71
  Yes 3 (33%) 4 (27%) 0.82 0.2–3.41 0.787 0.28 0.05–1.59 0.153 56
Surgery
  Group A 8 (67%) 13 (72%) 1 1 154
  Group B 4 (33%) 5 (28%) 0.89 0.26–2.98 0.848 4.90 0.55–44 0.156 103
Residual disease
  R0 9 (75%) 16 (89%) 1 1 154
  R1 3 (25%) 2 (11%) 3.57 0.88–14.47 0.074 2.80 0.66–11.89 0.162 38
Fissure invasion
  ≤3 cm 5 (42%) 17 (94%) 1 154
  >3 cm 7 (58%) 1 (6%) 6.95 2.02–23.96 0.002a 64
pT
  T2 9 (75%) 13 (72%) 1 1 154
  T3-T4 3 (25%) 5 (28%) 1.35 0.36–5.02 0.657 0.78 0.2–3.1 0.730 109
pN
  N0 6 (50%) 11 (61%) 1 1 154
  N1 3 (25%) 5 (28%) 1.31 0.33–5.26 0.702 0.22 0.03–1.56 0.131 109
  N2 3 (25%) 2 (11%) 6.22 1.27–30.41 0.024 1.42 0.22–9.07 0.711 36
p-Stage
  IB 4 (33%) 6 (33%) 1 1 154
  IIA 2 (17%) 5 (28%) 0.67 0.12–3.7 0.645 0.25 0.03–1.89 0.178 103
  IIB 2 (17%) 2 (11%) 5.56 0.82–37.44 0.078 3.27 0.39–27.54 0.275 33
  IIIA 4 (33%) 5 (28%) 1.95 0.48–7.92 0.349 0.61 0.11–3.37 0.575 109
Tumor size
  ≤4 cm 7 (58%) 8 (44%) 1 1 103
  >4 cm 5 (42%) 10 (56%) 1.70 0.54–5.38 0.365 1.23 0.36–4.19 0.741 154
Histology
  SCC 5 (42%) 4 (22%) 1.88 0.45–7.97 0.389 2.57 0.55–12 0.230 103
  AC 4 (33%) 5 (28%) 1.66 0.37–7.49 0.509 1.91 0.39–9.31 0.422 109
  Other 3 (25%) 9 (50%) 1 1 154
aAdjusting covariate: Fissure Invasion. Statistical tests: Cox regression analysis; statistical significance: p < 0.05.
SCC, squamous cell carcinoma; AC, adenocarcinoma.
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both procedures, and as opposed to the evidence mentioned by 
other authors, three of 12 patients undergoing a LWR and nine 
of 28 patients undergoing a bilobectomy or pneumonectomy 
experienced a recurrence (p = ns). As already reported for the 
DSS analysis, the type of resection did not affect the recur-
rence rate and the presence of FI extended for more than 3 cm 
was found to be the most significant prognostic factor. On the 
other hand, we have reported that the postoperative course of 
both procedures did not differ in terms of complication rate, 
hospital stay, and admission in ICU.
It has been proven that the task of the preoperative func-
tional assessment is to identify patients who are at increased 
risk of both perioperative complications and long-term dis-
ability from surgical resections of NSCLC. The ACCP guide-
lines16 recommended the spirometric tests in all patients 
undergoing lung resection, in particular for analyzing FEV1 
and DLCO. In fact, patients with FEV1 more than 80% pre-
dicted or more than 2 liters are suitable for resection includ-
ing pneumonectomy without further physiologic evaluation. 
On the contrary, if either the FEV1 or DLCO is less than 80% 
predicted or PaCO
2
 is more than 45 mmHg (factors related to 
high postoperative complication rate), it is recommended that 
postoperative lung function be predicted through additional 
testing. According to these guidelines, we have analyzed the 
baseline and the postoperative (1 month after discharge) pul-
monary function tests. The baseline preoperative tests were 
found to be comparable between both groups: in fact, pre-
operative FEV1%-predicted of group A and group B were, 
respectively, 92.5% ± 21.0% and 85.2% ± 20.0% (p = ns). 
Concerning the postoperative course of the total sample, we 
did not find any statistical correlation between FVC% less 
than 85%, FEV1% less than 85%, DLCO less than 15 or 
pO
2
 less than 80 mmHg, and complication rate or hospital 
stay. Indifferently from previous works, we have calculated 
the decline ΔFEV1% after surgery to compare both pro-
cedures in term of functional outcome. The ΔFEV1% was 
slightly higher in patients undergoing anatomical resection 
(−24.9% ± 13.5%) if compared with those undergoing LWR 
(−19.5% ± 13.3%), but this difference was not statistically 
significant (p = ns). Similar results were found when compar-
ing the decline of FVC%, DLCO, and pO
2
 as well.
Considering the akin oncological results of both proce-
dures, these data strongly support the evidence that anatomi-
cal or nonanatomical resection could lead to an acceptable and 
similar functional outcome in patients with NCSLC with FI. 
Thus, because radical resection of tumors with their lymphatic 
drainage is the accepted oncological procedure, bilobectomy 
or pneumonectomy should be performed in NSCLC patients 
with adjacent lobe invasion, whereas, in case of poor base-
line function tests, LWR may be preferable over an anatomical 
resection when the extent of FI is less than 3 cm. In the light 
of the new evidence reported,17 further studies are needed to 
evaluate the effect of a preoperative pulmonary rehabilitation 
in patients with FI and poor lung tests.
This study has several limitations. First, even if this work 
addresses the questions of how much the type of resections 
influences long-term survival outcome, recurrence, and early-
term outcome of pulmonary function, the number of cases 
is limited. Studies with larger sample sizes would be more 
sensible in detecting statistically significant differences and 
could lead to different conclusions. Furthermore, due to the 
small number of patients, it has not been possible to perform 
a subgroup analysis to assess the prognostic impact of FI on 
the T-factor, by excluding patients with lymph node involve-
ment: further studies with a large number of cases are needed 
to investigate this issue as well. Second, this study is retro-
spective, and the type of surgery was decided by the surgeon’s 
preference without randomization. Moreover, as reported by 
others,13 our pathological analysis lacks of data concerning the 
fissure completeness.
In conclusion, surgical strategy in NSCLC patients 
with FI is really a challenging issue. Our results suggest that 
nonanatomical resection (LWR) could be considered as a 
feasible surgical option (especially in “frail” patients with an 
extent of FI less than 3 cm) in the light of the similar onco-
logical and functional outcome compared with anatomical 
resection (bilobectomy or pneumonectomy). However, pro-
spective studies with a large number of patients are needed 
to confirm these preliminary data and also to investigate the 
impact of the two different surgical strategies on the postop-
erative quality of life.
FIGURE 2.  Disease-free survival curves according to type of 
surgery (A) and extent of fissure invasion (B).
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